BPX-201

N/A

Report date: 2022/08/30 20:00:42

Base Information

Drug NameBPX-201

Drug Alias NameBPX-201AP-1903 activated BPX-201

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulantsCytotoxic T lymphocytes stimulants

TargetsNot applicable

Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBellicum Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBellicum Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsProstatic Neoplasms, Castration-Resistant

Other Information

ATC CodeN/A